Senotherapeutics for healthy ageing

The recent manuscript by Childs et al. in Nature Reviews Drug Discovery1 thoroughly reviewed the important role senescent cells play in driving ageing and age-related diseases. The review also highlighted the clinical importance of developing senotherapeutic approaches to selectively kill senescent cells (senolytics) or to suppress the senescence-associated secretory phenotype (SASP) that drives sterile inflammation associated with ageing (senomorphics), in order to extend healthspan and potentially lifespan. Clearly, senotherapeutic approaches can revolutionize how age-related diseases and ultimately how ageing itself can be treated. Given how quickly the field of senotherapeutics is moving towards clinical trials, we would like to expand upon several important issues regarding the current and future development of senotherapeutics. This is particularly important since the nascent field of senotherapeutics is faced with the challenge of establishing important standards and criteria for documenting a compound's or a combination of compounds' function as advertised, that is, as senotherapeutics.

It is established that senescent cells play a causative role in ageing and age-related disease. Therefore, the development of drugs that specifically kill senescent cells is envisioned to have significant therapeutic effects on slowing ageing phenotypes, treating age-related comorbidities and improving resiliency. However, not all senescent cells are the same, expressing different senescence markers, secreting different SASP factors and, more importantly, using different senescent cell anti-apoptotic pathways (SCAPs) to resist apoptosis. The elimination of senescent cells from multiple tissues or even a single tissue will probably require the combination of multiple senotherapeutic drugs2.

To date, seven classes of compound with some evidence of senolytic activity have been reported (see Supplementary Table 1), including the combination of dasatinib and quercetin, as well as BCL2 family inhibitors, identified using a bioinformatics approach for SCAPs2. In addition, a forkhead box protein O4 (FOXO4)-interacting peptide, which blocks the association of FOXO4 with p53, induces apoptosis of senescent human cells in vitro and reduces the expression of senescence markers while extending healthspan in vivo. The natural compounds fisetin3, a quercetin-related flavonoid, and piperlongumine also exhibit evidence of senolytic or senomorphic activity in certain cell types in vitro. Clinically used compounds targeting the co-chaperone heat shock protein 90 (HSP90) were also identified as a novel class of potential senolytics, able to induce apoptosis of senescent murine and human cells in vitro and improve healthspan in vivo4. Finally, the FDA-approved histone deacetylase inhibitor panobinostat induces apoptosis of senescent tumour cells in vitro. Clearly, there are multiple SCAP targets and thus it is highly likely that additional classes of potential senolytics will be identified through bioinformatic analyses and drug-screening approaches.

Several classes of senomorphics — drugs that suppress markers of senescence or their secretory phenotype without inducing apoptosis — have also been identified. Senomorphics include inhibitors of IkB kinase (IKK) and nuclear factor (NF)-kB5, free radical scavengers and Janus kinase (JAK) pathway inhibitors6. Even rapamycin acts as a senomorphic by reducing the SASP. Some compounds, for example fisetin, have senomorphic effects on some cell types while having senolytic activity on others, at least in vitro3.

It is important to note that definitively demonstrating that a drug is senolytic or senomorphic is challenging and should be approached critically. Simply measuring a reduction in senescence markers (such as the expression of p16INK4A or p21CIP1 or SASP factors) or in senescence-associated β-galactosidase (SA-β-gal) activity is inadequate to distinguish between the two mechanisms of action. Careful determination of whether there is selective loss of senescent cells is required. Notably, the assay selected to test potential therapeutics influences the outcome. For example, the cell type selected and the method used to induce senescence influences which SCAPs are expressed and therefore whether a particular class of drugs (for example, BCL2 inhibitors) will be effective in killing cells. Also, the end points measured will influence interpretation (for example, senescence markers, SASP, number of viable cells and/or apoptosis markers) as well as what control cells are used (for example, proliferating or quiescent). Thus, the assays used and end points measured should be taken into careful consideration when defining a senolytic or senomorphic drug and the likelihood of its broad efficacy.

Once evidence is found for senolytic activity of a compound in vitro, it is even more difficult to document potential senolytic activity in vivo (Table 1). Demonstrating that a compound reduces the number of SA-ß-gal+ cells or the level of p16ink4a expression, such as through the use of p16ink4a–luciferase reporter mice, does not definitively demonstrate killing, let alone selective killing, of senescent cells. Also, since senolytics are cell type-specific, the lack of an effect on a specific tissue doesn't preclude senolytic activity in other tissues. Even more rigorous approaches, such as the injection of labelled senescent cells followed by drug treatment, only serve to document that the putative senolytic is functioning in vivo similar to in vitro, that is, by killing that specific type of transplanted senescent cell. Eventually, improved methods for colocalization of apoptosis and senescence in vivo at the single cell level, such as through the use of cytometry by time-of-flight (CyTOF) or dual fluorescent reporters, will be needed to define a compound as senolytic.

Table 1 Approaches for demonstrating the mechanism of action of senotherapeutics.

One current tactic to provide evidence that a compound has senolytic activity is the 'hit-and-run' approach, for example, the one-time treatment of mice with dasatinib and quercetin following hind-leg irradiation3. Here, a single administration of dasatinib plus quercetin yielded a therapeutic benefit that endured for months in terms of treadmill performance, consistent with a senolytic mechanism in which disease-causing cells are killed. In general, if a short course of treatment yields a sustained reduction in senescence, it is likely acting in a senolytic manner. In contrast, if chronic treatment is needed to suppress senescence markers or prevent secondary senescence, this is more consistent with senomorphic activity. However, more refined approaches are needed to rapidly demonstrate senolytic activity in vivo. Likely combinations of approaches may be necessary. For example, if a drug kills senescent endothelial cells, it could yield a health dividend, but it will be very difficult to document a reduction in the expression of senescence markers specifically in the endothelium without sophisticated reporter systems.

Another current approach to provide evidence that a compound potentially has senolytic activity in vivo is to compare the therapeutic efficacy of the drug to outcomes yielded by genetic ablation of senescent cells in transgenic INK-ATTAC or p16-3MR mice7,8. For example, in the bleomycin mouse model of idiopathic pulmonary fibrosis, the therapeutic benefit of treatment with dasatinib and quercetin is comparable to clearing senescent cells in INK-ATTAC mice9. However, it will still be important to determine if the same cell types are targeted in the INK-ATTAC and the dasatinib and quercetin-treated mice. In fact, the mechanism of cell clearance in INK-ATTAC mice differs fundamentally from mice treated with senolytic agents. In the transgenic models, cells with high p16ink4a promoter activity are targeted, while senolytics act by killing cells expressing specific pro-survival SCAPs. Importantly, not every cell with high p16ink4a expression is senescent and not every senescent cell has high p16ink4a expression. For example, p16INK4A and SA-β-gal activity are induced in macrophages as part of a reversible response to physiological stimuli even though these cells are not senescent10.

An additional approach to provide evidence of senolytic activity in vivo involves the use of human tissue explants harbouring senescent cells7. A putative senolytic should attenuate senescence markers while inducing apoptosis. However, while this approach documents senolytic activity of a compound, it does not identify the types of cell undergoing cell death and whether it is only a subset of senescent cells. Additional methods, including flow cytometry and CyTOF-based approaches, are needed to define the cell types within a tissue explant that are targeted by senotherapeutics, as well as to colocalize markers of senescence and apoptosis.

Proving that a compound exhibits in vivosenolytic activity is further complicated by potential indirect effects on the immune system. Functional immune cells, including natural killer and T lymphocytes, can remove senescent cells. However, as the immune system ages, the ability to clear senescent cells wanes, contributing to the accumulation of senescent cells. It is possible that some drugs, for example, rapamycin, reduce the burden of senescent cells indirectly by improving immune cell function. Similarly, inhibiting the SASP might improve immune clearance of senescent cells. Thus, demonstrating that a drug directly targets senescent cells must address the possibility that the drug improves host clearance of senescent cells.

All in all, there is reason to be tremendously excited about the health and economic impact of senotherapeutic drugs. However, as noted, caution is warranted in interpreting the mechanism of action and relative specificity, selectivity and efficacy. Furthermore, there is still much to learn about how best to identify, characterize and apply these drugs to improve human health.

References

  1. 1

    Childs, B. G. et al. Senescent cells: an emerging target for diseases of ageing. Nat. Rev. Drug Discov. 16, 718–735 (2017).

    CAS  Article  Google Scholar 

  2. 2

    Zhu, Y. et al. The Achilles' heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell 14, 644–658 (2015).

    CAS  Article  Google Scholar 

  3. 3

    Zhu, Y. et al. New agents that target senescent cells: the flavone, fisetin, and the BCL-XL inhibitors, A1331852 and A1155463. Aging 9, 955–963 (2017).

    Article  Google Scholar 

  4. 4

    Fuhrmann-Stroissnigg, H. et al. Identification of HSP90 inhibitors as a novel class of senolytics. Nat. Commun. 8, 422 (2017).

    Article  Google Scholar 

  5. 5

    Tilstra, J. S. et al. NF-kappaB inhibition delays DNA damage-induced senescence and aging in mice. J. Clin. Invest. 122, 2601–2612 (2012).

    CAS  Article  Google Scholar 

  6. 6

    Xu, M. et al. JAK inhibition alleviates the cellular senescence-associated secretory phenotype and frailty in old age. Proc. Natl Acad. Sci. USA 112, E6301–E6310 (2015).

    CAS  Article  Google Scholar 

  7. 7

    Jeon, O. H. et al. Local clearance of senescent cells attenuates the development of post-traumatic osteoarthritis and creates a pro-regenerative environment. Nat. Med. 23, 775–781 (2017).

    CAS  Article  Google Scholar 

  8. 8

    Baker, D. J. et al. Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature 479, 232–236 (2011).

    CAS  Article  Google Scholar 

  9. 9

    Schafer, M. J. et al. Cellular senescence mediates fibrotic pulmonary disease. Nat. Commun. 8, 14532 (2017).

    CAS  Article  Google Scholar 

  10. 10

    Hall, B. M. et al. p16(Ink4a) and senescence-associated beta-galactosidase can be induced in macrophages as part of a reversible response to physiological stimuli. Aging 9, 1867–1884 (2017).

    CAS  Article  Google Scholar 

Download references

Acknowledgements

This work was supported by National Institutes of Health grants P01-AG043376, U19-AG056278 and AG044376 and by the Glenn Foundation.

Author information

Affiliations

Authors

Corresponding authors

Correspondence to Laura J. Niedernhofer or Paul D. Robbins.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary information

Compounds for which evidence of senolytic activity has been reported (PDF 230 kb)

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Niedernhofer, L., Robbins, P. Senotherapeutics for healthy ageing. Nat Rev Drug Discov 17, 377 (2018). https://doi.org/10.1038/nrd.2018.44

Download citation

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing